Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension
The new antidiabetic drugs, gliflozins, inhibit sodium-glucose transporter-2 in renal proximal tubules promoting glucose and sodium excretion. This leads not only to a significant improvement of glucose control but also to the reduction of blood pressure and body weight in both diabetic patients and...
Guardado en:
Autores principales: | Silvie Hojná, Hana Rauchová, Hana Malínská, Irena Marková, Martina Hüttl, František Papoušek, Michal Behuliak, Denisa Miklánková, Zdeňka Vaňourková, Jan Neckář, Michaela Kadlecová, Petr Kujal, Josef Zicha, Ivana Vaněčková |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e201a9068c7440d880c7984feaa998e8 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia
por: Martina Hüttl, et al.
Publicado: (2021) -
Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes
por: Kwong-Man Ng, et al.
Publicado: (2018) -
Empagliflozin in type 1 diabetes
por: Mathieu C, et al.
Publicado: (2019) -
Empagliflozin: a new strategy for nephroprotection in diabetes
por: Anton Ivanovich Korbut, et al.
Publicado: (2017) -
Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model
por: Liu Y, et al.
Publicado: (2021)